Greenland Technologies regains compliance with Nasdaq listing rules » 08:0202/0302/03/23
Greenland Technologies Holding previously announced that it had received a letter on January 4 from the Staff of The Nasdaq Stock Market notifying the Company that it was not in compliance with the annual meeting requirement set forth in Nasdaq Listing Rule 5620 for continued listing on Nasdaq. The Company announced that on February 1 Nasdaq informed the Company that it is now back in compliance with Nasdaq Listing Rule 5620 following its Annual General Meeting held on January 31, 2023 and this matter is now closed.
1847 Holdings files to sell 7.93M shares of common stock for holders 16:4802/0102/01/23
1847 Holdings files $150M mixed securities shelf 16:3902/0102/01/23
Hillstream BioPharma signs option agreement with Dana-Farber Cancer Institute » 07:1701/3101/31/23
Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream's Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis. This approach combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long term responses and cures. "We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber," said Randy Milby, CEO of Hillstream. "This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients."
Genprex initiated with a Buy at Dawson James » 07:5101/3001/30/23
Dawson James analyst…
Dawson James analyst Jason Kolbert initiated coverage of Genprex with a Buy rating and $3 price target. The company's oncology platform utilizes a non-viral Nanoparticle Delivery System and its lead program in oncology, REQORSA Immunogene Therapy, or GPX-001, has been shown to be complementary with targeted drugs and immunotherapies, the analyst tells investors in a research note. REQORSA is currently enrolling clinical patients in two trials initially exploring its utility in NSCLC with a range of agents and the FDA has granted Fast Track Designation for both trials, the firm noted. The company also has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells and its planned phase 1 trial "represents the first-ever gene therapy tested in humans for diabetes," Dawson James said.
|Over a week ago|
1847 Holdings provides update on special warrant dividend » 08:4501/2301/23/23
1847 Holdings provides an…
1847 Holdings provides an update on the previously announced issued dividend in the form of warrants to purchase the Company's common shares at $4.20 per common share. Ellery Roberts, CEO and Chairman of the Board of the Company, commented, "We believe that issuing this special warrant dividend to our loyal shareholders may help to expose those who may have participated in what we believe to be market manipulation relating to the Company's common shares. Through our engagement with ShareIntel, we are able to obtain share trading analytic metrics that are designed to better monitor trading activity. If you are a registered shareholder and have not received your warrants, please contact [email protected] If you hold shares through a brokerage firm, bank, dealer or other similar organization, please reach out to your representative at such firm."
BioSig Technologies gives updates to highlight recent achievements » 08:5501/1901/19/23
BioSig Technologies issued an update to shareholders highlighting recent milestones and ongoing company developments. "January 2023 marks the one-year anniversary of redefining our product development and commercial strategies led by John Sieckhaus and Gray Fleming, respectively. During this time, we have built new sales and clinical teams, introduced new corporate and product branding, launched potentially game-changing software, secured numerous evaluations, established new research protocols, signed purchase agreements, and created a promising revenue pipeline. These are milestones never seen before at BioSig and we believe there are many more exciting ones ahead. While we are proud of the commercial progress BioSig has made over the past twelve months, 2022 proved to be a challenging year for the economy, and especially for Life Sciences companies like ours. This was reflected in our valuation. History shows us that innovative companies and technologies can prevail following economic downturns. The sharp market declines in 2000-2002 and 2008-2009 were followed by economic recoveries where new leaders emerged. We are confident that BioSig will be one of those emerging leaders based on the exciting commercial, technology and corporate activities underway in 2023'" said the company.
Longeveron announces publication of final data from ELPIS I trial » 08:4101/1901/19/23
Longeveron announced the…
Longeveron announced the publication of the full results from the Company's ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome in the European Heart Journal Open. In the uncontrolled open-label Phase 1b study entitled "Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial," patients underwent the Glenn Procedure at approximately 4-5 months old, and received intracardiac injections of Lomecel-BTM. The ELPIS I study was conducted by a consortium of leading pediatric cardiac surgeons led by Sunjay Kaushal, M.D., Ph.D., currently Division Head of Cardiovascular-Thoracic Surgery at Lurie Children's and principal investigator of the ELPIS I study. The findings of the study included: None of the children experienced the prespecified safety endpoint over one year of follow-up. The procedure was generally well-tolerated in all ten study participants. The babies maintained their weight-for-age z-score after the surgery, and all were alive and transplant-free one year following the procedure. Several indices of right ventricular function, notably the tricuspid regurgitation fraction, showed suggestions of either improvement or prevention of deterioration over one-year following the surgery. In a sub-study of 6 babies, a blood test showed evidence of the persistence and activity of Lomecel-BTM one week after injection. Longeveron is currently enrolling patients in the ELPIS II trial, a 38-patient, randomized, blinded, controlled Phase 2a clinical trial intended to evaluate the safety and efficacy of intramyocardial injection of Lomecel-BTM in infants with HLHS who are undergoing the Glenn Procedure. This ongoing trial is funded by a grant from the National Heart, Lung, and Blood Institute. Lomecel-BTM for HLHS has received Fast Track, Rare Pediatric Disease, and Orphan Drug Designations from the U.S. Food and Drug Administration.
1847 Cabinets engages ThinkEquity to explore strategic alternatives » 08:4701/1101/11/23
1847 Holdings announced…
1847 Holdings announced that its subsidiary 1847 Cabinets has engaged ThinkEquity to evaluate strategic options, including a potential sale, spin-off or other strategic transaction in order to capitalize on its internal growth and favorable outlook for the business. 1847 Cabinet Inc. is comprised of the businesses of Kyle's, High Mountain and Innovative Cabinets. Kyle's, which is based in Boise, Idaho, provides a wide variety of construction services including custom design and build of kitchen and bathroom cabinetry, delivery, installation, service and repair, extended warranties, and financing. High Mountain, which is based in Reno, Nevada, specializes in all aspects of finished carpentry products and services, including doors, door frames, base boards, crown molding, cabinetry, bathroom sinks and cabinets, bookcases, built-in closets, and fireplace mantles, among others, as well as window installation. Innovative Cabinets, also based in Reno, Nevada, specializes in custom cabinetry and countertops. Ellery Roberts, CEO and Chairman of the Board of the Company, commented, "We continue to grow and improve the profitability of our portfolio companies. Nevertheless, we believe there is a disconnect between how the public markets are valuing 1847 Holdings, and 1847 Cabinet's intrinsic value, let alone our other portfolio companies. Given the success of 1847 Cabinets, we believe the time is right to investigate a range of strategic alternatives for this subsidiary in order to maximize value and returns for our shareholders."
BioSig executes agreement with Bellin for acquisition of PURE EP technology » 08:3801/1001/10/23
BioSig Technologies announced that Bellin Health System in Green Bay, Wisconsin has signed an agreement to acquire the Company's PURE EP System. The agreement follows a 60-day formal evaluation of the PURE EP System at Bellin Health. The hospital reported that the PURE EP demonstrated a significant cost savings per case as well as a substantial reduction in noise and signal interference compared to the use of conventional systems only. The agreement grants Bellin Health full autonomy with respect to its operation of the PURE EP System, and BioSig will not be required to provide an on-site clinical account manager following the new system install. "Bellin has observed, first-hand, that clear cardiac signals provide more information that can impact procedural efficiency without driving up procedural costs," commented Gray Fleming, Chief Commercial Officer, BioSig Technologies. "The terms of this agreement represent a new milestone for the PURE EP(TM) System-expanding the accessibility and automaticity of our novel digital signal processing technology."